Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction

Xinsong Chen, Emmanouil G. Sifakis, Stephanie Robertson, Shiyong Neo, Seong-Hwan Jun, Le Tong, Apple H.m. Tay, John Lövrot, Roxanna Hellgren, Sara Margolin, Jonas Bergh, Theodoros Foukakis, Jens Lagergren, Andreas Lundqvist, Ran Ma, Johan HartmanProceedings of the National Academy of Sciences 2022 · DOI

TL;DR

Researchers have developed a novel "whole-tumor cell culture" (WTC) model that can be reliably established from breast tumors, preserving the tumor's microenvironment and genetic makeup. This WTC model allows for rapid (10-day) and personalized drug testing, showing strong correlation with patient responses, offering a promising tool for guiding breast cancer treatment.

What Problem Does This Paper Address?

Breast cancer (BC) is a highly heterogeneous disease, meaning treatments that work for one patient may not work for another. While many anti-cancer drugs exist, predicting individual patient response remains a significant challenge, often leading to ineffective treatments and unnecessary side effects. Existing patient-derived models, like cell lines or patient-derived xenografts (PDXs), have limitations: cell lines don't fully represent the tumor's complexity, and PDXs are costly, variable, and slow to establish. The paper addresses the need for a more accurate, efficient, and clinically relevant ex vivo model that can recapitulate the tumor's native microenvironment and genetic landscape to predict drug response.

Methods

The core innovation is the Whole-Tumor Cell Culture (WTC) model. This method involves:

  • Tumor Scraping: Cells are collected from fresh tumor biopsies using a superficial scraping technique, allowing for the use of even small tumors.
  • Ex Vivo Culturing: The scraped cells are cultured ex vivo for 4-5 days. Crucially, this method aims to maintain the endogenous microenvironment, including tumor cells, immune cells, fibroblasts, and endothelial cells, as confirmed by flow cytometry and immunofluorescence.
  • Drug Profiling: Once established, WTCs are exposed to various drugs for 96 hours.
  • Drug Sensitivity Score (DSS): Cell viability assays are performed, and a DSS is calculated to quantify drug efficacy.
  • Genomic and Transcriptomic Analysis: Whole-genome sequencing (WGS) and RNA sequencing are used to confirm that WTCs retain the genetic and gene expression profiles of the original tumors, including copy number alterations (CNAs) and somatic mutations.
  • Validation Study: The WTC model's predictive power was validated by comparing ex vivo drug profiling results with the actual clinical responses of 15 patients undergoing neoadjuvant therapy.

Datasets

The study utilized:

  • Patient Tumor Biopsies: Samples from 116 breast cancer patients for WTC establishment and characterization.
  • Paired Tumor and WTC Samples: Used for genomic (WGS) and transcriptomic (RNA-seq) comparisons to assess model fidelity.
  • A Pilot Cohort of 45 Patients: For drug profiling and gene expression analysis.
  • A Validation Cohort of 15 Patients: Undergoing neoadjuvant therapy, whose ex vivo WTC drug responses were compared to their clinical outcomes.
  • NanoString BC360 Panel Data: For pathway analysis on FFPE tissue samples from drug-profiled patients.

No new benchmark datasets were introduced; rather, the study leverages existing patient samples and clinical data for validation.

Key Insights and Ideas

  • Preserving the Microenvironment is Key: Unlike simpler ex vivo models, WTCs successfully retain a diverse population of stromal and immune cells, mimicking the in vivo tumor microenvironment (TME). This is crucial because the TME significantly influences drug response and resistance.
  • Rapid Turnaround Time: The ability to generate a drug response profile within 10 days is a significant advantage over current methods, making it feasible for clinical decision-making.
  • Genomic and Transcriptomic Fidelity: The WTC model remarkably recapitulates the genetic landscape (CNAs, mutations) and gene expression patterns of the original tumors, ensuring its biological relevance.
  • Predictive Power for Neoadjuvant Therapy: The validation study demonstrated a strong correlation between WTC-based drug sensitivity scores and actual patient responses to neoadjuvant chemotherapy, particularly for epirubicin. This suggests the model can reliably predict treatment outcomes.
  • Stratification Potential: The WTC model, combined with genomic and transcriptomic data, can help stratify patients into subgroups that might benefit from specific therapies or clinical trials.

Key Results

  • High Success Rate: WTCs were successfully established from 98 out of 116 (84.5%) breast tumors.
  • Biomarker Retention: Key biomarkers like ER, PR, Ki67, and HER2 were maintained in WTCs, albeit with slight decreases in some cases.
  • Genomic Concordance: WTCs showed high concordance (average 79%) with parental tumors for somatic mutations and highly similar copy number alterations.
  • Transcriptomic Concordance: WTCs clustered with their paired tumor samples, and conserved PAM50 gene expression profiles were observed in most cases.
  • Drug Sensitivity Prediction: WTC drug profiling showed significant correlations with patient responses, particularly for epirubicin in the neoadjuvant validation study, where higher DSSs predicted better clinical outcomes (pCR/pPR).
  • Venetoclax Responsiveness: Drug sensitivity to venetoclax (a BCL-2 inhibitor) correlated with BCL2 transcript abundance and ER positivity.

Limitations and Future Work

  • Long-Term Culture Challenges: The authors acknowledge that long-term culture and passaging can be difficult, especially for maintaining stromal cell populations.
  • Testing Certain Drug Classes: The model's ability to fully represent the efficacy of angiogenesis-targeted and immunomodulatory drugs is limited due to the lack of complete tumoral vasculature and physical barriers.
  • Clinical Trial Assignment: While promising, the WTC model requires further clinical validation before it can be routinely used for patient treatment decisions or assignment to clinical trials.
  • Future Directions: The authors propose further development of the WTC model for high-throughput drug screening, patient stratification, and biomarker validation. They also suggest its potential for academic research and pharmaceutical drug development.

Summary updated

Abstract

Breast cancer (BC) is a complex disease comprising multiple distinct subtypes with different genetic features and pathological characteristics. Although a large number of antineoplastic compounds have been approved for clinical use, patient-to-patient variability in drug response is frequently observed, highlighting the need for efficient treatment prediction for individualized therapy. Several patient-derived models have been established lately for the prediction of drug response. However, each of these models has its limitations that impede their clinical application. Here, we report that the whole-tumor cell culture (WTC) ex vivo model could be stably established from all breast tumors with a high success rate (98 out of 116), and it could reassemble the parental tumors with the endogenous microenvironment. We observed strong clinical associations and predictive values from the investigation of a broad range of BC therapies with WTCs derived from a patient cohort. The accuracy was further supported by the correlation between WTC-based test results and patients' clinical responses in a separate validation study, where the neoadjuvant treatment regimens of 15 BC patients were mimicked. Collectively, the WTC model allows us to accomplish personalized drug testing within 10 d, even for small-sized tumors, highlighting its potential for individualized BC therapy. Furthermore, coupled with genomic and transcriptomic analyses, WTC-based testing can also help to stratify specific patient groups for assignment into appropriate clinical trials, as well as validate potential biomarkers during drug development.
BibTeX
@inproceedings{chen2022breast,
  author = {Xinsong Chen and Emmanouil G. Sifakis and Stephanie Robertson and Shiyong Neo and Seong-Hwan Jun and Le Tong and Apple H.M. Tay and John Lövrot and Roxanna Hellgren and Sara Margolin and Jonas Bergh and Theodoros Foukakis and Jens Lagergren and Andreas Lundqvist and Ran Ma and Johan Hartman},
  title = {{Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2022},
  doi = {10.1073/pnas.2209856120},
}
Figure